Dinani apa ngati iyi ndi nkhani yanu yosindikiza!

Rheumatoid Arthritis New Clinical Trial

Lynk Pharmaceuticals Co., Ltd. (yomwe tsopano imadziwika kuti 'Lynk Pharmaceuticals'), kampani yotsogola yachipatala, yalengeza kuti kampaniyo yapatsa wodwala woyamba LNK01001 mu mayeso ake a Phase II omwe ali ndi nyamakazi ya nyamakazi (RA). LNK01001 ndi choletsa chandamale chochizira matenda a autoimmune.

Sangalalani, PDF ndi Imelo

Kafukufuku wachipatala adapangidwa kuti awunikire chitetezo ndi mphamvu ya LNK01001 mwa anthu omwe ali ndi nyamakazi yamtundu wapakati kapena yoopsa kwambiri omwe salabadira kapena kusalolera mankhwala ochiritsira ochiritsira ochiritsira (csDMARDs).

LNK01001 ndiye mankhwala oyamba opangidwa ndi Lynk Pharmaceuticals, ndipo amasankha kinase inhibitor pochiza matenda a autoimmune. M'mbuyomu, LNK01001 idamaliza maphunziro a Phase I m'maphunziro athanzi m'chilimwe cha chaka chino ku China komanso ku Australia ndi Japan, mothandizidwa ndi Lynk Pharmaceuticals ndi mnzake waku US, motsatana. Zotsatira zinasonyeza kuti mankhwalawa ndi otetezeka komanso amalekerera. Kuphatikiza apo, LNK01001 idavomerezedwa ndi National Medical Products Administration of China (NMPA) pakuwunika kwachipatala zatsopano - ankylosing spondylitis (AS) ndi atopic dermatitis (AD).

Pulofesa Xiaofeng Zeng ndi wofufuza wamkulu wa kafukufukuyu komanso mkulu wa Dipatimenti ya Rheumatology and Immunology ya Peking Union Medical College Hospital ndi Chinese Academy of Medical Sciences.

Sangalalani, PDF ndi Imelo

Ponena za wolemba

Linda Hohnholz, mkonzi wa eTN

Linda Hohnholz wakhala akulemba ndi kusintha zolemba kuyambira pomwe anayamba ntchito. Iye wagwiritsa ntchito chilakolako chobadwachi m'malo ngati Hawaii Pacific University, Chaminade University, Hawaii Children's Discovery Center, ndipo tsopano TravelNewsGroup.

Siyani Comment